Table 1.

Annual price changes for MS DMTs. Annual prices estimated using wholesale acquisition cost (first DataBank). Inflation adjustment and estimates from US bureau of labor statistics CPI.

DMT (approval year)	Approval annual price per patient (2020 US dollars)	2020 current annual price per patientc	1997–2001	2002–2005	2006–2009	2010–2016	2017–2020
CPI Inflation			1.7%	2.8%	2.4%	1.6%	2.1%
Branded products
Interferon beta-1b (1993)	$19,509	$103,302	0.0%	11.5%	17.8%	15.2%	6.9%
Interferon beta-1a (1996)	$13,608	$91,835	0.0%	11.3%	18.2%	16.1%	2.0%
Glatiramer acetate (1996)	$12,772	$86,554	4.7%	18.9%	17.5%	14.9%	0.0%
Interferon beta-1a SC (2002)	$20,019	$103,647		9.6%	13.7%	15.6%	4.8%
Natalizumab (2006)a	$31,740	$89,074		0.0%	7.9%	11.3%	3.5%
Interferon beta-1b (2009)b	$35,668	$81,079				14.4%	6.0%
Fingolimod (2010)	$56,784	$105,390				9.0%	5.5%
Teriflunomide (2012)	$50,304	$93,296				16.6%	5.0%
Dimethyl fumarate (2013)	$60,677	$100,690				13.4%	6.0%
Glatiramer 40 mg (2014)	$66,541	$75,816				7.9%	0.0%
Peginterferon beta-1a (2014)	$67,283	$91,835				14.8%	2.0%
Alemtuzumab (2014)	$71,916	$80,320				2.5%	5.1%
Ocrelizumab (2017)	$68,778	$65,000					0.0%
Siponimod (2019)	$89,812	$93,367					5.5%
Cladribine (2019)	$100,975	$107,460					8.0%
Diroximel fumarate (2019)	$88,000	$88,000					NA
Median	$58,731	$91,835	0.0%	11.3%	17.5%	14.6%	5.0%
Generic products
Glatopa 20 mg (2015)	$68,901	$18,250					−71.1%
Glatopa 40 mg (2018)	$67,793	$19,500					−70.2%
Gen glatiramer 20 (2017)	$66,090	$23,725					−62.5%
Gen glatiramer 40 (2017)	$68,432	$25,350					−61.3%

^aNatalizumab was originally approved in 2004, but withdrawn after 2 months to evaluate progressive multifocal leukoencephalopahy risks. It was reintroduced in June 2006.

^bNovartis’ Extavia™.

^cJanuary 2020.

CPI, consumer price index; DMT, disease-modifying therapies; MS, multiple sclerosis; NA, not applicable; US, United States.